Sanofi India Ltd
Q3 FY25, unaudited
- Revenue
- ₹514.90 Cr
- Profit after tax
- ₹91.30 Cr
As filed with the exchange, consolidated basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q3 FY25 | vs a year ago | FY25 |
|---|---|---|---|
| Revenue from operations | 514.90 | — | 2,013.20 |
| Other income | 5.90 | — | 16.50 |
| Total income | 520.80 | — | 2,029.70 |
| Employee benefit expense | 53.80 | — | 240.20 |
| Finance costs | 0.40 | — | 1.50 |
| Depreciation & amortisation | 9.60 | — | 36.70 |
| Total expenses | 406.60 | — | 1,560.60 |
| Profit before tax | 122.20 | — | 431.40 |
| Tax expense | 30.90 | — | 117.70 |
| Profit after tax | 91.30 | — | 413.30 |
| Total comprehensive income | 98.50 | — | 420.50 |
| Earnings per share, basic | ₹39.64 | ₹179.46 |
|---|---|---|
| Earnings per share, diluted | ₹39.60 | ₹179.46 |
Q3 FY25 and FY25 — unaudited, from the company’s filing with NSE. Source
Q3 FY25 results for every company Parakho holds
Why the dash
Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.
Earnings call
Q1 FY27Sanofi India reported quarter two 2026 results with diabetes business growth of close to 14%, driven by Toujeo and Soliqua, while the partnership business with Emcure and Cipla grew 2% in the quarter. Profit before tax and exceptional items rose 19% year-on-year to INR 112 crores from INR 94 crores, with margin improving to 27% of net sales from 24%. Management discussed export market challenges in Australia offset partly by other markets, and noted cash balance grew 34%.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.
Filings
12 shown · 60 published by the exchange
09 Oct 2026
07 Oct 2026
29 Sept 2026
28 Sept 2026
28 Sept 2026
Insider tradingDisclosure Under Regulation 7(2)(B) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015
Appears 2 times in the recent filings shown; listed once.
25 Sept 2026
25 Sept 2026
Insider tradingDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Appears 3 times in the recent filings shown; listed once.
25 Sept 2026
25 Sept 2026
Insider trading21 Sept 2026
18 Sept 2026
08 Sept 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Industry
Healthcare › Pharmaceuticals
Classification as published by BSE.
Companies also in Pharmaceuticals, in alphabetical order
Page generated from filings held to 09 Oct 2026.